INS and Hyperglycemia: Hyperglycemia was the most frequent treatment-related adverse event (51.5%), alongside nausea, decreased appetite, diarrhea, and vomiting; importantly, hyperglycemia was manageable through dose adjustment, treatment interruption, and concomitant antidiabetic medication (e.g., metformin or insulin).